These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 37217796

  • 1. In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
    Liang R, Wang D, Hu M, Gu Y, Wang M, Hu D, Zhu M, Wang M.
    J Antibiot (Tokyo); 2023 Sep; 76(9):540-547. PubMed ID: 37217796
    [Abstract] [Full Text] [Related]

  • 2. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [Abstract] [Full Text] [Related]

  • 3. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
    Lee SY, Gill CM, Nicolau DP, ERACE-PA Global Study Group.
    J Antimicrob Chemother; 2023 Dec 01; 78(12):2795-2800. PubMed ID: 37840005
    [Abstract] [Full Text] [Related]

  • 4. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.
    Bonnin RA, Bernabeu S, Emeraud C, Creton E, Vanparis O, Naas T, Jousset AB, Dortet L.
    Int J Antimicrob Agents; 2022 Oct 01; 60(4):106660. PubMed ID: 35988666
    [Abstract] [Full Text] [Related]

  • 5. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS.
    Int J Antimicrob Agents; 2021 Nov 01; 58(5):106439. PubMed ID: 34547421
    [Abstract] [Full Text] [Related]

  • 6. Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii.
    Zalacain M, Achard P, Llanos A, Morrissey I, Hawser S, Holden K, Toomey E, Davies D, Leiris S, Sable C, Ledoux A, Bousquet J, Castandet J, Lozano C, Everett M, Lemonnier M.
    Antimicrob Agents Chemother; 2024 Mar 06; 68(3):e0112023. PubMed ID: 38289044
    [Abstract] [Full Text] [Related]

  • 7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb 06; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 8. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
    Sader HS, Carvalhaes CG, Kimbrough JH, Mendes RE, Castanheira M.
    Int J Antimicrob Agents; 2024 Apr 06; 63(4):107113. PubMed ID: 38354826
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48.
    Asempa TE, Kois AK, Gill CM, Nicolau DP.
    J Antimicrob Chemother; 2023 Mar 02; 78(3):636-645. PubMed ID: 36626311
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Enterobacterales Isolates.
    Teo JQ, Chang HY, Tan SH, Tang CY, Ong RT, Ko KKK, Chung SJ, Tan TT, Kwa AL.
    Microbiol Spectr; 2023 Jun 15; 11(3):e0100223. PubMed ID: 37184408
    [Abstract] [Full Text] [Related]

  • 17. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
    Bonnin RA, Bernabeu S, Emeraud C, Naas T, Girlich D, Jousset AB, Dortet L.
    Antibiotics (Basel); 2023 Jan 06; 12(1):. PubMed ID: 36671303
    [Abstract] [Full Text] [Related]

  • 18. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C, Freire S, Nordmann P, Poirel L.
    Eur J Clin Microbiol Infect Dis; 2024 Feb 06; 43(2):339-354. PubMed ID: 38095831
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.
    Kuo SC, Wang YC, Tan MC, Huang WC, Shiau YR, Wang HY, Lai JF, Huang IW, Lauderdale TL.
    J Antimicrob Chemother; 2021 Jul 15; 76(8):2071-2078. PubMed ID: 33956969
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex.
    Méndez-Sotelo BJ, Delgado-Beltrán M, Hernández-Durán M, Colín-Castro CA, Esquivel-Bautista J, Ortega-Oliva SA, Ortiz-Álvarez J, García-Contreras R, Franco-Cendejas R, Lopez Jacome LE.
    PLoS One; 2024 Jul 15; 19(4):e0298577. PubMed ID: 38635685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.